ADVERTISEMENT

Rheumatoid arthritis: European approval for high concentration biosimilar formula

Deepa Varma   |   Medical News   |   07 April 2023
ADVERTISEMENT

The European Commission has authorised the marketing of the citrate-free high concentration formulation (HCF) of Hyrimoz (adalimumab) in the European Union. Hyrimoz is biosimilar to the already approved drug Humira. The approval covers all the indications treated by the reference medication (Humira), including rheumatic diseases, Crohn's disease, ulcerative colitis, plaque...

          

Topic Challenges

left
right